Catalent, Inc.

Catalent, Inc.

CTLT

$63.48

Updated: 24/09/2026, 18:07:43

Market Cap
$11.52B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US

No historical data available

Company Profile

Catalent, Inc., operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services. The Softgel and Oral Technologies division focuses on the formulation, development, and manufacturing of soft capsules. These are utilized in a diverse range of client products, such as prescription medications, over-the-counter drugs, nutritional supplements, unit-dose cosmetics, and medicinal preparations for animal health. Within the Biologics segment, Catalent undertakes the creation of biologic cell lines, develops and manufactures both cell therapy and viral-based gene therapy, and handles the formulation and production of parenteral dose forms, including vials, prefilled syringes, and cartridges. This segment also provides essential analytical development and testing capabilities. The Oral and Specialty Delivery segment offers extensive formulation, development, and manufacturing expertise across various technologies. It provides integrated downstream solutions spanning clinical development and commercial supply. This segment also features a dedicated oral delivery solutions platform, encompassing preclinical screening, formulation, analytical development, and current good manufacturing practices (cGMP) services. Finally, the Clinical Supply Services segment delivers vital support for drug and biologic clinical trials. Its services include manufacturing, specialized packaging, secure storage, efficient distribution, and comprehensive inventory management. This segment also offers "FastChain," a demand-led clinical supply service. Catalent serves a broad client base, including pharmaceutical, biotechnology, and consumer health organizations, alongside companies in other healthcare sectors like animal health and medical devices, and even the cosmetics industry. The company was founded in 2007 and maintains its headquarters in Somerset, New Jersey.

USD
NYSE
CEO: Alessandro Maselli
Employees: 17,000
https://www.catalent.com
Asset Summaries
Latest generated summaries for CTLT

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for CTLT.
Share price
$63.48
Market cap
$11.52B
Exchange
NYSE
Currency
USD
CEO
Alessandro Maselli
Employees
17,000
IPO date
31/07/2014
Beta
1.158
Last dividend
$0.00
Day range
$63.44 – $63.50
52-week range
$42.11 – $63.50
1-day performance
0.00%
1-year performance
50.75%
Current drawdown (1Y)
-0.03%
CIK
0001596783
CUSIP
148806102
ISIN
US1488061029
Created
07/12/2025, 03:29:15
Last update
24/09/2026, 18:07:43

Track Catalent, Inc. with an AI analyst

See which prediction-market events move CTLT, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to CTLT from your Railway `news_articles` table.

No news found for this symbol.